Table 6. Comparison of PTC recurrence between the BRAF^V600E mutation and PD-L1 expression alone and combined.

Group comparison	HR	95% CI	P value
Early PTC
Group 1 vs. Group 2	0.683	0.076–6.115	0.733
Group 1 vs. Group 3	0.786	0.337–1.837	0.579
Group 1 vs. Group 4	1.267	0.841–1.909	0.257
Group 2 vs. Group 4	1.704	0.598–4.858	0.319
Group 3 vs. Group 4	3.315	0.689–15.958	0.135
Group 2 vs. Group 3	0.887	0.080–9.779	0.922
PTMC
Group 1’ vs. Group 2’	0.030	0–13655.040	0.597
Group 1’ vs. Group 3’	0.146	0–49.834	0.518
Group 1’ vs. Group 4’	1.464	0.806–2.659	0.211
Group 2’ vs. Group 4’	7.674	0.073–807.719	0.391
Group 3’ vs. Group 4’	112.910	0.007–NA	0.341
Group 2’ vs. Group 3’	–	–	–

PTC, papillary thyroid carcinoma; PD-L1, programmed death-ligand 1; HR, hazard ratio; CI, confidence interval; PTMC, papillary thyroid microcarcinoma; NA, unable to calculate.